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Aromatic amines, N-nitroso compounds and heterocyclic amines
are suspected human pancreatic carcinogens. Cytochrome P450
(CYP) 1A2, N-acetyltransferase (NAT) 1, NAT2 and sulfotransfer-
ase (SULT) are enzymes involved in the metabolism of these car-
cinogens. To test the hypothesis that genetic variations in
carcinogen metabolism modify the risk of pancreatic cancer
(PC), we investigated the effect of single-nucleotide polymor-
phisms (SNPs) of the CYP1A2, NAT1, NAT2 and SULT1A1 gene
on modiﬁcation of the risk of PC in a hospital-based study of
755 patients with pancreatic adenocarcinoma and 636 healthy
frequency-matched controls. Smoking and dietary mutagen expo-
sure information was collected by personal interviews. Genotypes
were determined using the polymerase chain reaction–restriction
fragment length polymorphism and Taqman methods. Odds ra-
tios (ORs) and 95% conﬁdence intervals (CIs) were estimated
using unconditional multivariate logistic regression analysis. We
observed no signiﬁcant main effects of any of these genes on the
risk of PC. The CYP1A2 and NAT1 but not SULT1A1 and NAT2
genotypes showed signiﬁcant interactions with heavy smoking in
women not men. In contrast, a signiﬁcant interaction between
NAT1 genotype and dietary mutagen intake on modifying the risk
of PC were observed among men but not women. The OR
(95% CI) of PC was 2.23 (1.33–3.72) and 2.54 (1.51–4.25) for
men having the NAT1 10 and a higher intake of 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene, re-
spectively, compared with individuals having no NAT1 10 or
a lower intake of these dietary mutagens. These data suggest the
existence of gender-speciﬁc susceptibility to tobacco carcinogen
and dietary mutagen exposure in PC.
Introduction
Pancreatic cancer (PC) causes 33 700 deaths/year in USA, making it
the fourth most common cause of cancer deaths; furthermore, the
mortality rate for PC has remained unchanged over the past few
decades (1). Understanding the etiology and identifying the risk fac-
tors are essential for the primary prevention of this deadly disease.
Cigarette smoking, a major source of carcinogen exposure, is the
only environmental risk factor for PC that has been consistently im-
plicated in epidemiological studies (2). Cigarette smoke contains
many toxic constituents, including 43 known carcinogens (3). Carci-
nogenic aromatic amines (AAs) and tobacco-speciﬁc nitrosamines
detected in cigarette smoke are hypothesized to be major causal fac-
tors in the etiology of various cancers (4). Previous studies by our
group (5,6) and a study by other investigators (7) showed that indi-
vidual variations in carcinogen-metabolizing genes modify the risk of
smoking-related PC.
Another suspected risk factor for PC is diet (8). Epidemiological
studies have shown an association between increased risk for PC and
high consumption of salt, smoked meat, dehydrated food, fried food
and reﬁned sugar (9–11). In particular, meat cooked at high temper-
atures,such asbarbecued or deep-fried meat,isasourceofcarcinogenic
heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons
(PAHs) (12,13). Processed or smoked meat could also serve as a source
of N-nitroso compounds (NOCs), represented by nitrosamines, a sus-
pected class of pancreatic carcinogens (14). Notably, the high frequency
of K-ras mutation in human PCs parallels that found in pancreatic
tumors in hamsters induced by NOCs (15). However, investigations
pursuing estimates of dietary NOC intakes were impeded by the lack
of a good study instrument. The major subclass of HCAs found in
the human diet comprises the aminoimidazoazaarenes 2-amino-3-
methylimidazo[4,5-f]quinoline, 2-amino-3,4-dimethylimidazo[4,5-
f]quinoline, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx),
2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx) and
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) (16,17). The
pancreas is highly susceptible to HCA-induced DNA damage, and
studies have shown that HCA compounds induce pancreatic
tumors and promote tumor growth in animals (18,19). Furthermore,
benzo[a]pyrene (BaP) is one of the most potent PAH animal carci-
nogens (20), and dietary exposure to it causes increased tumor for-
mation at several sites, particularly in the gastrointestinal tract, in
animal models (21). Using a well-established meat preparation ques-
tionnaire and a relevant database, dietary intake of HCAs and PAHs
has been associated with increased risk of PC (22,23). Therefore, the
current study examined exposures only to dietary HCAs and PAHs.
Genetic factors that inﬂuence individual susceptibility to dietary
mutagen exposure-associated PC are unclear. Cytochrome P450
(CYP) 1A2, N-acetyltransferase (NAT) and sulfotransferase (SULT)
are enzymes involved in the detoxiﬁcation as well as bioactivation of
AAs, HCAs and NOCs (24–27). Usually, these carcinogens are acti-
vated by N-hydroxylation catalyzed by hepatic CYP (28). Alterna-
tively, they are either N-acetylated or N-sulfated by NAT or SULT,
respectively, for detoxiﬁcation. However, following N-hydroxylation,
they can be O-acetylated or O-sulfated by the same enzymes, yielding
highly reactive intermediates capable of binding to DNA (29).
More than 40 single-nucleotide polymorphisms (SNPs) of the
CYP1A2 gene have been identiﬁed. Because many of the SNPs are
in linkage disequilibrium, CYP1A2 1D and CYP1A2 1F have been
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assessment (30). We have demonstrated previously that presence of
the CYP1A2 1F allele has additive effects on increased risk of PC
among smoking women (5). Two NAT isoenzymes—NAT1 and
NAT2—are found in humans. The former is expressed in all human
tissues, including the pancreas (31), whereas the latter is expressed
primarily in liver and gastrointestinal tract (32,33). Both NAT1
and NAT2 catalyze the O-acetylation of a number of carcinogenic
N-hydroxy AAs and HCAs (34). The NAT1 and NAT2 genes are
located on chromosomes 8p23.1-p21.3 and 8p22, respectively, and
both are encoded by single open reading frames of 870 bp that
exhibit genetic polymorphisms in human populations (35). Molecular
epidemiological studies demonstrated that individuals with NAT1
rapid acetylator genotypes or NAT2 slow acetylator genotypes and
exposed to known AA and HCA carcinogens, such as in cigarette
smoke, diet or occupation, were at increased risk for various types
of human cancers (36,37). In our previous studies, NAT1 rapid acety-
lator genotype and NAT2 slow acetylator genotype were associated
with a signiﬁcantly increased risk of PC among heavy smokers (5,6).
SULT1A1belongs to a gene superfamily involved in the sulfonation
of hormones, neurotransmitters, drugs and xenobiotic compounds.
O-sulfation is a common step in phase II enzyme detoxiﬁcation; how-
ever, sulfate anions may be cleaved off heterolytically and release
electrophils that may bind to DNA (38). Also, studies showed that
G638A leading to an amino acid change from arginine to histidine at
codon 213 (Arg213His) was associated with reduced enzyme activity
and thermostability (39,40). A number of studies of SULT1A1 poly-
morphisms and cancers of the lung, colon, prostate, bladder, esopha-
gus and urinary tract have had conﬂicting results (41–46).
To identify genetic factors involved in carcinogen exposure-
associated PC, we examined SNPs of the CYP1A2, NAT and SULT
genes in association with AA and HCA exposures in a hospital-based
PC case–control study.
Materials and methods
Study population
The study population and design were described in detail previously (23).
Cases were patients with pathologically conﬁrmed primary pancreatic ductal
adenocarcinoma and were recruited consecutively from the Gastrointestinal
Center at The University of Texas MD Anderson Cancer Center from 2000
to 2006. No restrictions on the recruitment of patients with respect to age, race
or sex were used. Also, healthy controls were recruited from among the
spouses, friends and non-blood relatives of patients with various types of
cancers other than gastrointestinal cancers or other smoking-related cancers.
Eligible controls were identiﬁed using a brief screening questionnaire to col-
lect information on demographics, cancer history, state of residence, relation-
ship to the respective patient and willingness to participate in a research
project. The controls were frequency matched with the cases by age at enroll-
ment (5-year interval), sex and race. All study participants were residents of
USA and were able to communicate in English. Written informed consent for
interviews and a blood sample were obtained from each participant. The study
was approved by the MD Anderson Cancer Center Institutional Review Board.
Data collection
A trained study coordinator administered a structured risk factor questionnaire
to collect demographic data and information on cigarette smoking, alcohol
consumption, occupational history, medical history and family history of can-
cer. Both patients and controls were interviewed by the same study personnel.
No proxy interviews were conducted. Cumulative smoking was calculated in
pack-years, i.e. the number of packs smoked per day multiplied by the number
of years of smoking. Those who had smoked for .20 pack-years were con-
sidered to be heavy smokers. The individuals who consumed .60 g/day alco-
hol were deﬁned as heavy drinkers. Information on dietary mutagen exposure
was collected in personal interviews using a meat preparation questionnaire
(23). The questionnaire provided information on daily consumption of MeIQx,
PhIP, DiMeIQx and BaP as well as a mutagenic index (revertant colonies
per grams of daily meat intake), which was calculated using previously
obtained laboratory information regarding the mutagenic activity of meat sam-
ple extracts in a standard Ames assay with Salmonella typhimurium strain
TA98 (47).
DNA extraction and genotyping assays
Blood samples were collected in heparinized vacutainers (BD Biosciences,
Franklin Lakes, NJ). Peripheral blood mononuclear cells were separated from
freshly drawn blood using Ficoll-Hypaque density gradient centrifugation
(Amersham Pharmacia Biotech, Piscataway, NJ). DNA was extracted from
mononuclear cells using a FlexiGene DNA kit (Qiagen, Valencia, CA) and
the Maxwell 16 automated system (Promega, Madison, WI).
CYP1A2 1F polymorphism (rs762551) was determined by polymerase
chain reaction (PCR)–restriction fragment length polymorphism (5) and
Taqman (48) methods as described previously. Probes and oligonucleotides
were obtained from Applied Biosystems (Foster City, CA) using the Assay-by-
Design product. The PCR ampliﬁcation was done using the ABI Prism 7900
HT sequence detector.
Genotyping of SULT1A1 for polymorphisms at G638A was performed by
PCR–restriction fragment length polymorphism method. The primers used for
ampliﬁcation of the target fragment were SULT F 5#-GGGTTTCTAGGA-
GAAGTGGC-3# and SULT R 5#-GAGATGCTGTGGTCCATGA-3#, which
produce a 275 bp exon 7 region of the SULT1A1 gene containing the G638A
site. PCR was performed in a 20 ll reaction mixture containing 100 ng DNA,
0.25 lM each primer, 50 lM each deoxy nucleotide triphosphate (dNTP) and
0.4 U Taq DNA polymerase with 1.5 mM MgCl2 containing 10  ammonium
reaction buffer (Gene Choice, Frederick, MD). The reaction was carried out
under the following conditions: an initial melting step for 6 min at 94C
followed by 32 cycles for 45 s at 94C, 35 s at 62C and 30 s at 72C and a
ﬁnal elongation for 7 min at 72C. The PCR products were then digested using
the restriction enzyme HhaI (New England Biolabs, Beverly, MA) overnight
and separated on a 2.5% agarose gel. The wild-type G allele had an HhaI
restriction site that resulted in two bands (155 and 115 bp, respectively); the A
allele lackedanHhaI restriction site and thus produceda single 270 bp fragment.
The laboratory personnel were blinded to the case–control status of the samples.
Eight SNPs of the NAT1 gene (C97T, C190T, G445A, C559T, G560A,
A752T, T1088A and C1095T) and seven SNPs of the NAT2 gene (G191A,
C282T, T341C, C481T, G590A, A803G and G857A) were analyzed using
Taqman as described previously (49,50). About 10% of the samples were
analyzedin duplicate,andinconsistent resultsfromﬁvesampleswereexcluded
from the ﬁnal risk analysis. The NAT1 10 allele or NAT2 slow acetylation
alleles (NAT2 5,  6,  7 and  14 clusters) were considered to be the ‘at-risk’
alleles.
Statistical analysis
Chi-square tests were used to compare the distribution of categorical variables
and genotype frequencies in the patients and controls. Unconditional multivar-
iate logistic regression analysis was used to calculate odds ratios (ORs) and
95% conﬁdence intervals (CIs). The basic statistical models were adjusted for
sex, race (white, Hispanic, black and Asian), age ( 50, 51–60, 61–70 and .70
years), smoking status (non-smoker,  20 pack-years and .20 pack-years),
alcohol consumption (never,  60 g/day and .60 g/day), history of diabetes
(yes or no) and family history of cancer among ﬁrst-degree relatives(yes or no)
when appropriate. Dietary mutagen intake variables were dichotomized using
the 60th percentile of the control value as the cutoff as reported previously
(23). Genotype-related evaluations were restricted to non-Hispanic white par-
ticipants because of a small number of minority participants. To explore the
potential gene–environment interaction according to smoking status (never
smoker versus ever smoker), number of pack-years (0,  20 and .20) and
dietary intake of HCAs ( 60th or .60th percentile of the control value), the
cross-product term for genotype and the variable of interest was generated in
unconditional logistic regression models. A two-by-four table was constructed
to evaluate the scale of interaction (i.e. the departure from an additive or
multiplicative model). The signiﬁcance of the interaction term was determined
usinga likelihoodratiotest, withthefullmodel containingthe interactionterm,
the main effect of genotype, the exposure variable and the reduced model
lacking the interaction term. OR trends were examined using the score test
with adjustment for other risk factors, treating the interaction term as a contin-
uous variable.
To explore the possible interactions of the many environmental and genetic
factors involved in this study, we used logic regression (51) to ﬁnd the best
logical combination of factors that predicted case–control status. The method
works by searching all possible combinations of factors joined by ‘and/or’
operators and ﬁnding the one that yielded the best separation between cases
and controls. The method results in a new composite predictor ‘L’ that is
a single dichotomous factor in a logistic regression. We then ran a permutation
test (1000 permutations) to obtain a P value for this composite factor that takes
the multiple testing aspect of logic regression into account. Factors that were
considered in the analysis included smoking, dietary mutagen exposure, family
history of cancer among ﬁrst-degree relatives, diabetes, alcohol and genotype.
Pack-years were selected as the reﬂection of smoking status. Non-smoker, light
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ered two different cut-points for deﬁning light smokers and heavy smokers:
20 or 40 pack-years. For dietary mutagen exposure, the inﬂuence of individual
mutagen intake (MeIQx, DiMeIQx, PhIP and BaP) and overall mutagenicity
(revertants per gram per day) was considered separately. We used the median
or the third quartile in controls as potential group cut-point for each of those
variables. Alcohol consumption was consideredby groupsof non-drinker, light
drinker and heavy drinker, using .60 ml ethanol/day as the cutoff for heavy
drinkers. For the genetic variables, both dominant and recessive models for
each genetic marker were considered.
All statistical analyses were performed using the Stata 9.0 (StataCorp,
College Station, TX), R and SAS software programs. All tests were two sided
and P values ,0.05 were indicative of statistical signiﬁcance.
Results
Characteristics of the study subjects and genotype frequency
We performed this study in 755 patients with pancreatic adenocarci-
noma and 636 healthy frequency-matched controls; their demograph-
ics and potential risk factors for PC and genotype frequency are listed
inTable I. Weobservedno signiﬁcant differences between the patients
and controls according to age, sex or alcohol consumption, but we did
according to race, family history of cancer, history of diabetes and
smoking status. The mean ages of the patients and controls (±standard
deviation) were 62.1 ± 10.2 years and 60.9 ± 10.1 years, respectively
(P 5 0.89). Although the number was small, there were fewer mi-
nority controls than minority patients (8 versus 14%) because of
the known challenges in minority recruitment. All genotype distribu-
tions in controls followed the Hardy–Weinberg equilibrium among
non-Hispanic white participants. We observed no signiﬁcant dif-
ferences between patients and controls in the distribution of these
genotypes.
Interaction of genotypes with smoking
Next, we examined the association between these genotypes and the
risk of PC in relation to cigarette smoking in the non-Hispanic white
patients and controls. We conﬁrmed our previously reported observa-
tions that a signiﬁcant trend of increased risk of PC was associated
with smoking and CYP1A2 and NAT genotypes in women but not
in men (Table II and Figure 1). Heavy smokers among women
(.20 pack-years) carrying the CYP1A2 1F AA genotype had an ad-
justed OR of 4.36 (95% CI 5 2.15–8.84) compared with never smok-
ers carrying the AC or CC genotypes. Also, heavily smoking women
with the NAT1 10 allele had a 4-fold higher risk (OR, 4.01; 95% CI 5
1.73–9.29) of PC when compared with never smokers who did not
carry the NAT1 10 allele. In addition, all the gene–smoking interac-
tions were statistically signiﬁcant at the multiplicative scale among
women.
Genotype and dietary mutagen exposure
The mean intake of dietary mutagens (MeIQx, DiMeIQx, PhIP and
BaP) and mutagenicity index in consumed meat were higher in pa-
tients than in controls as we reported previously (23). When we di-
chotomized dietary mutagen intake according to the 60th percentile of
control values, PhIP and BaP intake was associated with a 1.37-fold
(95% CI 5 0.99–1.91) and 1.64-fold (95% CI 5 1.19–2.26) increased
risk of PC, respectively, in men but not women (data not shown).
Consequently, we examined the joint effect of dietary mutagen intake
and genotype in male non-Hispanic white participants only (Table III
and Figure 1). Of the four genes investigated, NAT1 10 showed sig-
niﬁcant interaction with each of the ﬁve parameters of mutagen ex-
posure in modifying the risk of PC. Individuals carrying the NAT1 10
allele and having a higher intake of (in the top 40%) dietary mutagens
had a 1.64- to 2.54-fold higher risk of PC than did those without the
NAT1 10 allele and had lower levels of dietary mutagen intake. Fi-
nally, we did not observe any signiﬁcant interactions between the
CYP1A2 1F, SULT1A1 and NAT2 genotypes and dietary mutagen
intake in modiﬁcation of the risk of PC among men and we did not
observe a signiﬁcant interaction between any genotype and dietary
mutagen intake in women (data not shown).
Fitted logic regression model
Because our study involves multiple exposure and genetic factors, we
explored the gene–gene and gene–environmental interactions using
the logic regression approach (51). This method searches all possible
combinations of factors joined by and/or operators and identiﬁes the
best composite predictor L that is a single dichotomous factor. The
logistic regression model containing the newly created factor L is
shown in Table IV. The ﬁtted model indicated that subjects who have
[(history of diabetes 5 yes and SULT1A1 5 GA/GG) or (CYP1A2 1F
5 CA/AA and not a light smoker)] or [(heavy smoker or NAT2 5
rapid) and (heavy drinker or NAT1 5 any 10)] have a signiﬁcantly
increased risk of PC compared with the other group (OR 5 2.59,
P , 0.001 based on 1000 permutation tests). This predictor indicates
three distinct groups that demonstrated a greater probability of being
Table I. Distribution of selected variables among cases and controls
Variable Cases
(N 5 755)
Controls
(N 5 636)
P value
n (%) n (%)
Age at recruitment (years) 0.26
 50 103 (13.7) 103 (16.2)
51–60 221 (29.3) 194 (30.5)
61–70 260 (34.4) 219 (34.4)
.70 171 (22.6) 120 (18.9)
Gender 0.33
Female 320 (42.4) 253 (39.8)
Male 435 (57.6) 383 (60.2)
Race 0.004
Non-Hispanic white 649 (86.0) 585 (92.0)
Hispanic 47 (6.2) 24 (3.8)
Black 50 (6.6) 21 (3.2)
Other 9 (1.2) 6 (1.0)
Family history of cancer
a ,0.001
No 175 (23.3) 197 (31.0)
Yes 577 (76.7) 438 (69.0)
History of diabetes
b ,0.001
No 567 (75.1) 571 (90.0)
Yes 188 (24.9) 64 (10.0)
Smoking status ,0.001
Non-smokers 304 (40.3) 310 (48.7)
 20 pack-years 186 (24.6) 166 (26.1)
.20 pack-years 265 (35.1) 160 (25.2)
Alcohol consumption
c 0.345
Never 334 (44.2) 271 (43.6)
 60 g/day 362 (47.9) 313 (50.4)
.60 g/day 59 (7.9) 37 (6.0)
CYP1A2 1F
d 0.957
AA 341 (52.5) 307 (52.5)
AC 276 (42.5) 247 (42.2)
CC 32 (4.9) 31 (5.3)
Sult1A1 0.651
GG 248 (38.2) 228 (39.0)
GA 368 (56.7) 321 (54.9)
AA 33 (5.1) 36 (6.2)
NAT1 0.353
Non 10 431 (66.4) 403 (68.9)
 10 218 (33.6) 182 (31.1)
NAT2 0.797
Rapid 38 (5.9) 34 (5.8)
Intermediate 248 (38.2) 213 (36.4)
Slow 363 (55.9) 338 (57.8)
aInformation was missing for three cases and one control because of adopted
family.
bInformation was missing for one control.
cInformation was missing for 15 controls.
dDistribution for non-Hispanic white.
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GA/GG genotype; (ii) those who are not light smokers carrying the
CYP1A2 1F CA/AA genotype and (iii) those who are heavy smokers
or with the NAT2 rapid genotype and being either heavy drinkers or
possess the NAT1 10 allele. The case–control status broken out by
these three groups is shown in Table V.
Discussion
In this large-scale case–control study, we examined the effect of ge-
netic variations in carcinogen metabolism on the risk of PC associated
with cigarette smoking and dietary mutagen intake. We found a sig-
niﬁcantly increased risk of PC associated with smoking and dietary
Table II. Interaction of genotypes with cigarette smoking in non-Hispanic white participants
Genotype Smoke (pack-years) Male Female
Cases/controls, n OR (95% CI)
a Pinteraction Cases/controls, n OR (95% CI)
a Pinteraction
CYP1A2 1F 0.805 ,0.001
AC/CC Never 60/62 1.0 55/79 1.0
AA Never 78/86 0.99 (0.61–1.60) 60/62 1.35 (0.80–2.25)
AC/CC  20 50/43 1.11 (0.64–1.94) 31/27 1.51 (0.78–2.91)
AA  20 42/47 0.94 (0.53–1.64) 35/24 2.31 (1.21–4.42)
AC/CC .20 74/44 1.75 (1.03–2.97) 38/22 2.24 (1.15–4.38)
AA .20 81/72 1.06 (0.64–1.73) 45/16 4.36 (2.15–8.84)
Ptrend 0.430 ,0.001
SULT1A1 0.023 ,0.001
GG Never 59/52 1.0 43/53 1.0
GA/AA Never 79/96 0.76 (0.47–1.25) 72/89 0.97 (0.57–1.65)
GG  20 27/33 0.73 (0.38–1.41) 19/21 1.00 (0.46–2.19)
GA/AA  20 60/53 0.94 (0.54–1.62) 43/30 1.91 (1.00–3.62)
GG .20 49/48 0.84 (0.48–1.47) 38/19 2.45 (1.18–5.08)
GA/AA .20 97/69 1.21 (0.72–2.01) 44/18 2.96 (1.45–6.06)
Ptrend 0.330 ,0.001
NAT1 0.408 0.012
Non 10 Never 88/101 1.0 70/96 1.0
 10 Never 50/47 1.22 (0.74–2.02) 45/46 1.34 (0.78–2.29)
Non 10  20 62/56 1.18 (0.73–1.89) 45/38 1.64 (0.93–2.87)
 10  20 25/30 0.92 (0.49–1.73) 17/13 1.98 (0.89–4.44)
Non 10 .20 97/82 1.24 (0.81–1.90) 55/27 2.71 (1.50–4.89)
 10 .20 49/35 1.55 (0.91–2.66) 27/10 4.01 (1.73–9.29)
Ptrend 0.300 ,0.001
NAT2 0.021 0.002
R/I Never 62/53 1.0 56/65 1.0
Slow Never 76/95 0.65 (0.40–1.06) 59/77 0.81 (0.48–1.36)
R/I  20 39/38 0.80 (0.44–1.45) 23/21 1.47 (0.72–3.03)
Slow  20 48/48 0.77 (0.44–1.37) 39/30 1.34 (0.71–2.53)
R/I .20 58/51 0.87 (0.51–1.51) 39/16 2.71 (1.30–5.65)
Slow .20 88/66 1.03 (0.62–1.71) 43/21 2.27 (1.16–4.46)
Ptrend 0.622 0.001
R/I 5 rapid/intermediate.
aOR was adjusted for age, family history of cancer, history of diabetes and alcohol consumption.
Fig. 1. Interactive effects of NAT1 genotype with cigarette smoking (left panel) or dietary BaP intake (right panel) on risk of PC. NS, never smokers; LS, light
smokers( 20 pack-years); HS, heavy smokers (.20 pack-years); high,.52.10 ng/day(60th percentileof controls) ofBaP intake; low,  52.10 ng/day. Solid bars,
NAT1 non 10; open bars, NAT1 10.
Interaction of gene and mutagen exposure in pancreatic cancer
1187mutagen intake in women and men, respectively. Furthermore, we
observed a signiﬁcant interaction of the NAT1 genotype with dietary
mutagens in modiﬁcation of the risk of PC among men. These are the
ﬁrst reported data to demonstrate a sex difference in susceptibility to
dietary mutagen intake-related PC and in gene–diet interactions in
modiﬁcation of the risk of PC.
Previous epidemiological studies revealed a higher smoking-
related relative risk of PC in women than in men (52,53). Also, Duell
Table III. Interaction between genotype and dietary mutagen intake in men
Mutagen CYP1A2 F Cases/controls OR (95% CI)
a Pinteraction SULT1A1 Cases/controls OR (95% CI)
a Pinteraction
MeIQx
 44.98 AC/CC 72/67 1.0 0.148 GG 51/67 1.0 0.566
 44.98 AA 93/100 0.9 (0.6–1.4) GA/AA 114/100 1.4 (0.9–2.2)
.44.98 AC/CC 74/57 1.2 (0.7–1.9) GG 70/57 1.4 (0.8–2.4)
.44.98 AA 74/78 0.8 (0.5–1.3) GA/AA 78/78 1.2 (0.7–1.9)
Ptrend 0.753 0.450
DiMeIQx
 2.37 AC/CC 80/72 1.0 0.569 GG 53/69 1.0 0.995
 2.37 AA 86/107 0.8 (0.5–1.2) GA/AA 113/110 1.2 (0.8–1.9)
.2.37 AC/CC 66/52 1.1 (0.7–1.8) GG 68/55 1.4 (0.8–2.3)
.2.37 AA 81/71 0.9 (0.6–1.6) GA/AA 79/68 1.4 (0.8–2.3)
Ptrend 0.938 0.319
PhIP
 162.3 AC/CC 70/75 1.0 0.133 GG 62/77 1.0 0.902
 162.3 AA 88/105 0.9 (0.6–1.4) GA/AA 96/103 1.1 (0.7–1.7)
.162.3 AC/CC 76/49 1.6 (0.9–2.7) GG 59/47 1.5 (0.9–2.5)
.162.3 AA 79/73 1.1 (0.7–1.8) GA/AA 96/75 1.5 (0.9–2.4)
Ptrend 0.436 0.071
BaP
 52.10 AC/CC 67/71 1.0 0.440 GG 55/70 1.0 0.494
 52.10 AA 77/104 0.8 (0.5–1.2) GA/AA 89/105 1.0 (0.6–1.6)
.52.10 AC/CC 79/53 1.5 (0.9–2.4) GG 66/54 1.4 (0.9–2.4)
.52.10 AA 90/74 1.2 (0.8–2.0) GA/AA 103/73 1.7 (1.0–2.7)
Ptrend 0.197 0.016
Mutagenicity
 7141 AC/CC 70/71 1.0 0.169 GG 53/69 1.0 0.917
 7141 AA 86/99 0.9 (0.6–1.4) GA/AA 103/101 1.2 (0.8–1.9)
.7141 AC/CC 76/53 1.3 (0.8–2.2) GG 68/55 1.4 (0.8–2.4)
.7141 AA 81/79 0.9 (0.6–1.5) GA/AA 89/77 1.3 (0.8–2.2)
Ptrend 0.685 0.132
MeIQx NAT1 NAT2
 44.98 Non 10 115/115 1.0 0.005 R/I 64/68 Reference 0.355
 44.98 Any 10 50/52 1.0 (0.6–1.6) S 101/99 1.1 (0.7–1.7)
.44.98 Non 10 83/96 0.8 (0.5–1.2) R/I 66/54 1.3 (0.7–2.1)
.44.98 Any 10 65/39 1.6 (1.0–2.7) S 82/81 0.9 (0.6–1.6)
Ptrend 0.210 0.922
DiMeIQx
 2.37 Non 10 118/127 1.0 0.012 R/I 64/68 1.0 0.799
 2.37 Any 10 48/52 1.0 (0.6–1.7) S 102/111 0.9 (0.6–1.5)
.2.37 Non 10 80/84 0.9 (0.6–1.4) R/I 66/54 1.2 (0.7–2.1)
.2.37 Any 10 67/39 1.8 (1.1–3.0) S 81/69 1.1 (0.7–1.9)
Ptrend 0.142 0.885
PhIP
 162.3 Non 10 105/123 1.0 0.011 R/I 62/66 1.0 0.858
 162.3 Any 10 53/57 1.1 (0.7–1.7) S 96/114 0.9 (0.6–1.4)
.162.3 Non 10 93/88 1.1 (0.7–1.7) R/I 68/56 1.3 (0.7–2.1)
.162.3 Any 10 62/34 2.2 (1.3–3.7) S 87/66 1.3 (0.8–2.1)
Ptrend 0.018 0.293
BaP
 52.10 Non 10 98/117 1.0 0.004 R/I 57/69 1.0 0.592
 52.10 Any 10 46/58 0.9 (0.6–1.6) S 87/106 1.0 (0.6–1.6)
.52.10 Non 10 100/94 1.2 (0.8–1.8) R/I 73/53 1.7 (1.0–2.8)
.52.10 Any 10 69/33 2.5 (1.5–4.3) S 96/74 1.5 (0.9–2.4)
Ptrend 0.003 0.114
Mutagenicity
 7141 Non 10 105/115 1.0 0.005 R/I 59/64 1.0 0.592
 7141 Any 10 51/55 0.9 (0.6–1.6) S 97/106 1.0 (0.6–1.6)
.7141 Non 10 93/96 0.9 (0.6–1.4) R/I 71/58 1.3 (0.8–2.2)
.7141 Any 10 64/36 1.9 (1.2–3.2) S 86/74 1.1 (0.7–1.8)
Ptrend 0.045 0.510
R/I 5 rapid/intermediate; S 5 slow.
aOR was adjusted for age, family history of cancer, history of diabetes, smoking status and alcohol consumption.
H.Suzuki et al.
1188et al. (7) reported a signiﬁcant interaction between the GSTT1-null
genotype and heavy smoking in increasing the risk of PC in women
but not men. We showed previously, in a smaller sample of the current
study population, a stronger association between CYP1A2, NAT1/2
gene polymorphisms and smoking with PC in women than in men
(5) and these results were reconﬁrmed in this study. These observa-
tions suggest the existence of hormonal or other gender-speciﬁc fac-
tors that modulate the risk ofsmoking-related PC. In the present study,
we examined the effect of the phase II enzyme SULT1A1, which is
also involved in hormone metabolism, on the risk of smoking-related
PC. We found that the SULT1A1 Arg213His polymorphism did not
have a signiﬁcant main effect or interactive effect with smoking on the
risk of PC. Thus, determining the mechanism responsible for the sex
difference in susceptibility to smoking-related PC requires further
investigation.
We have reported previously the association between dietary mu-
tagen intake and PC risk that we observed in the present study pop-
ulation (23). Our new ﬁndings reported herein are the sex differences
in susceptibility to dietary mutagen intake-related PC and the effects
of genotype on PC risk modiﬁcation. For undetermined reasons, we
observed a higher PC risk related to dietary PhIP and BaP intake in
men than in women, which is directly opposite to the trend in smok-
ing, wherein we observed higher susceptibility to PC from cigarette
smoking in women than in men. This observation is consistent with
ﬁndings from a recent cohort study that total, red or high-temperature
cooked meat intake was positively associated with PC in men but not
women (54). A higher level of exposure to dietary mutagens or higher
levels of iron in men or sex differences in susceptibility to such ex-
posures were discussed as explanations to their observations (54).
When we compared the pack-years of smoking and dietary mutagen
intakeseparatelyinpatientsandcontrols,menconsistentlyhadahigh-
er level of exposure than women in all parameters examined (data not
shown). Thus, the association between dietary mutagen exposure and
risk of PC in men could be related to a higher level of exposure in this
group. In contrast, genetic differences in carcinogen metabolism
rather than differences in the exposure level between men and women
are more likely to be responsible for the sex differences in suscepti-
bilities to smoking because women actually had lower level of expo-
sure than men. However, we did not observe a sex difference in the
distribution of the CYP1A2 1F, NAT1, NAT2 and SULT1A1 genotypes
in patients of the current study (data not shown). Based on previously
reported evidence regarding hormonal regulation of NAT expression
in mammalian tissues (55), sex differences in dietary mutagen sensi-
tivity may relate to different patterns of expression of the NAT1 gene
in men and women. Other epidemiological studies of meat consump-
tion that have examined sex-speciﬁc PC risk have not demonstrated
clear sex differences (9,56–58). Thus, our observations must be con-
ﬁrmed in other study populations and for other genes involved in
dietary mutagen metabolism.
Of the fourgenes examined in the present study, NAT1 had the most
pronounced effect on the risk of PC in interaction with dietary
mutagen intake. This result is understandable because NAT1 is the
predominant NAT protein expressed in the human pancreas (31).
Pancreas is different from any other digestive organs because it does
not have direct contact with food carcinogens and all exposures are
blood borne. In this case, the carcinogen metabolic capacity in the
target tissue may play a more important role than the hepatic metab-
olism. Since NAT1 10 has been shown to confer a rapid acetylator
phenotype (59), the increased risk of PC associated with this allele
may be explained by a larger amount of reactive carcinogens activated
by NAT1 in the target tissue. Our results do not support a signiﬁcant
role for the CYP1A2 1F, SULT1A1 and NAT2 genotype with dietary
mutagen in modifying the risk of PC.
When multiple genetic and environmental factors were considered
in a logic regression approach, we observed possible interactions of
diabetes with SULT1A1 genotype and CYP1A2 1F genotype with
smoking in modifying the risk of PC. In addition, heavy smoking,
heavy drinking and NAT genotypes were also identiﬁed as signiﬁcant
contributors to the ﬁnal risk model. In contrast, none of the mutagen
exposure parameters were chosen by logic regression as the strongest
predictors of PC. The relationship of diabetes and SULT1A1 genotype
has not been reported previously. SULT enzymes catalyze the sulfate
conjugation of many hormones, neurotransmitters, drugs and xenobi-
otic compounds. The SULT1A1 gene encodes one of the two phenol
SULTs with thermostable enzyme activity. We speculate that the re-
duced enzyme activity conferred by the SULT1A1 variant alleles may
render the pancreatic cells more susceptible to some unknown xeno-
biotics or hormones since neither smoking nor dietary mutagen
exposure showed interaction with this genotype in modifying the risk
of PC.
Our study had several limitations. First, it was a hospital-based
study conducted in a single tertiary referral cancer center, so the data
may not be applicable to the general population. Second, we restricted
the genetic analysis to non-Hispanic white participants because of the
small number of minorities enrolled in the study. Third, we did not
consider information on body mass index or other dietary factors (e.g.
intake of calories, fat, fruits and vegetables, etc.). Fourth, the assess-
ment of exposure to dietary mutagen was limited to HCAs and PAHs.
Although NOC exposure could modify the risk of PC via modulation
of carcinogen metabolic enzymes or synergistic action with other
carcinogens, the role of NOC exposure on the risk association was
not considered in this study. Last but not least, dietary exposure to
HCAs and PAHs was assessed using self-reported data on eating
habits 1 year before the cancer diagnosis or control recruitment. This
type of assessment did not consider the lifetime exposure durations or
ﬂuctuations. As the sample size increases in our ongoing study and
a better study instrument is developed, some of these limitations may
be overcome.
In this large hospital-based PC case–control study, we found sig-
niﬁcant interactions of the CYP1A2 1F and NAT1 10 genotypes with
smoking among women and NAT1 genotype with dietary mutagen
intake among men. We also showed a number of genetic and envi-
ronmental factors that appear to be strong predictors of PC using
a logic regression model. These results suggest mechanisms of
pancreatic carcinogenesis but need to be conﬁrmed in other study
populations.
Table IV. Fitted logistic regression model for case–control in non-Hispanic
white participants
Variable Case, n (%) Control, n (%) OR P
L 5 0 332 (46) 390 (54) Reference
L 5 1 194 (69) 88 (31) 2.59 ,0.001
L 5 1: [(history of diabetes 5 yes and SULT1A1 5 GA/GG) or
(CYP1A2 1F 5 CA/AA and not a light smoker)] or [(heavy smoker or NAT2
5 rapid) and (heavy drinker or NAT1 5  10)]. L 5 0: except for above.
P value was calculated based on 1000 permutation tests. The 95th percentile
of OR in the permutation distribution was 1.27.
Table V. Case–control status for three components of composite predictor
from logic regression analysis
Variable Case,
n (%)
Control,
n (%)
History of diabetes 5 yes or
SULT1A1 5 GA/GG
419 (49) 432 (51)
History of diabetes 5 yes and
SULT1A1 5 GA/GG
107 (69) 46 (31)
CYP1A2 1F 5 CA/AA or a light smoker 504 (52) 470 (48)
CYP1A2 1F 5 CA/AA and not a light smoker 22 (73) 8 (27)
Not [(heavy smoker or NAT2 5 rapid)
and (heavy drinker or NAT1 5  10)]
440 (51) 432 (49)
[(Heavy smoker or NAT2 5 rapid)
and (heavy drinker or NAT1 5  10)]
86 (65) 46 (35)
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